Please login to the form below
33
Revenue 2017Humalog
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Humalog was produced by Lilly.
Lilly joins new Medicare scheme to reduce insulin prices
Lilly has faced particularly strong criticism, after its widely-used Humalog insulin rose from $34 to $234 per vial between 2001 and 2015.
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
Lilly needs to refresh its pipeline as it continues to suffer from a decline across its older, established brands – including in its diabetes franchise, where its Humalog insulin is facing generic ... The company recently announced its will launch lower
Lilly extends range of cut-price insulins in the US
Cheaper, authorised generic versions of Lilly’s Humalog Junior KwikPen and Humalog Mix75/25 products – priced at $265.20 for a pack of five which is another 50% reduction on the ... Humalog pay less than $100 for their monthly prescription at retail
Novo follows Sanofi, Lilly with insulin price cut in US
which offered a 50% cheaper version of its Humalog (insulin lispro) the following month.
The fight for affordable insulin
The price of Humalog, more commonly used by type 1 patients, also saw its price rise 585% from $35 to $234 between 2001 and 2015. ... Lilly’s authorised generic. One company, Eli Lilly, has responded to the pleas for more affordable insulins, and
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
